Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Modified Staging System for Waldenström Macroglobulinemia (MSS-WM): A Multi-Institutional Externally Validated Prognostic Model for Active/Symptomatic Waldenström Macroglobulinemia

Blood (2023) 142 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2023-179940

Published: 2023

Journal Articles

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

Carla Casulo, Jesse G. Dixon, Jennifer Le-Rademacher, Eva Hoster, Howard S. Hochster, Wolfgang Hiddemann, Robert Marcus, Eva Kimby, Michael Herold, Catherine Sebban, Emmanuel Gyan, Kenneth Foon, Tina Nielsen, Umberto Vitolo, Gilles A. Salles, Qian Shi, Christopher R. Flowers

Blood (2022) 139 (11): 1684–1693.

https://doi.org/10.1182/blood.2020010263

Published: 2022

Includes: Supplemental data

Journal Articles

A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Jennifer A. Woyach, Amy S. Ruppert, Gabriela Perez, Allison M Booth, Diane Feldman, Elie G Dib, Aminah Jatoi, Jennifer Le-Rademacher, Nyla A. Heerema, Cecelia Miller, Gerard Lozanski, Richard F. Little, Brian T. Hill, Wei Ding, Richard M. Stone, Sumithra J Mandrekar, John C. Byrd

Blood (2021) 138 (Supplement 1): 3728.

https://doi.org/10.1182/blood-2021-151471

Published: 2021

Journal Articles

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Blood (2019) 134 (Supplement_1): 4525.

https://doi.org/10.1182/blood-2019-129488

Published: 2019

Journal Articles

Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Jennifer Woyach, MD, Amy S. Ruppert, MAS, PhD, Gabriela Perez, MS, Allison M Booth, Diane Feldman, Elie G Dib, MD, Aminah Jatoi, MD, Jennifer Le-Rademacher, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Richard Little, MD, Wei Ding, MD PhD, Brian T. Hill, MD, Richard M. Stone, MD, Sumithra J Mandrekar, PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1751.

https://doi.org/10.1182/blood-2019-127102

Published: 2019

Journal Articles

Apixaban, Dalteparin, in Active Cancer Associated Venous Thromboembolism, the ADAM VTE Trial

Robert D. McBane, MD, Waldemar E. Wysokinski, MD PhD, Jennifer Le-Rademacher, PhD, Aneel A. Ashrani, MD, M.S., Alfonso J Tafur, MD MS, RPVI, FSVM, Krishna Gundabolu, MBBS, Juliana Perez-Botero, MD, Usha Perepu, MD, Daniel M. Anderson, MD MPH, Charles Kuzma, MD, Roberto leon Ferre, MD, Stanislav Henkin, MD, Charles Lenz, MD, Charles Loprinzi, MD

Blood (2018) 132 (Supplement 1): 421.

https://doi.org/10.1182/blood-2018-99-118808

Published: 2018

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study

Blood (2018) 132 (Supplement 1): 2170.

https://doi.org/10.1182/blood-2018-99-118383

Published: 2018

Journal Articles

Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials

Carla Casulo, MD, Jennifer Le-Rademacher, PhD, Jesse Dixon, Stat, Gilles Salles, MD, Eva Hoster, Michael Herold, MD, Wolfgang Hiddemann, Catherine Sebban, MD, Robert Marcus, Eva Kimby, Howard Hochster, MD, Umberto Vitolo, MD, Emmanuel Gyan, MDPhD, Fang-Shu Ou, PhD, Tina Nielsen, Kenneth A. Foon, MD, Shi Qiuan, PhD, Christopher Flowers, MD

Blood (2017) 130 (Supplement 1): 412.

https://doi.org/10.1182/blood.V130.Suppl_1.412.412

Published: 2017

Journal Articles

Transcriptome Analysis of Lymphoma Edited Monocyte Phenotype

Yi Lin, MD PhD, Amel Dudakovic, PhD, Roman Thaler, PhD, Ailing Xue, Jennifer Le-Rademacher, PhD, Levy D. Pederson, Dennis A. Gastineau, MD, Allan Dietz, PhD, Andre van Wijnen, PhD

Blood (2017) 130 (Supplement 1): 3575.

https://doi.org/10.1182/blood.V130.Suppl_1.3575.3575

Published: 2017

Journal Articles

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Blood (2017) 129 (26): 3419–3427.

https://doi.org/10.1182/blood-2017-02-765685

Published: 2017

Includes: Supplemental data

Journal Articles

Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial

Blood (2016) 128 (22): 1346.

https://doi.org/10.1182/blood.V128.22.1346.1346

Published: 2016

Journal Articles

PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485)

Blood (2016) 128 (22): 4392.

https://doi.org/10.1182/blood.V128.22.4392.4392

Published: 2016

Journal Articles

Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial

Blood (2016) 128 (8): 1050–1058.

https://doi.org/10.1182/blood-2015-08-664706

Published: 2016

Journal Articles

Autologous Hematopoietic Cell Transplantation in Patients with High Risk Multiple Myeloma: Post- Transplant Responses Do Not Translate to Longer Survival

Manish Sharma, MD, Parmeswaran Hari, MD MRCP, MS, Jennifer Le-Rademacher, PhD, Amrita Krishnan, Yago Nieto, MD PhD, Cristina Gasparetto, MD, Jiaxing Huang, MS, Emma C. Scott, MD, Anita D'Souza, MBBS, MD

Blood (2015) 126 (23): 1979.

https://doi.org/10.1182/blood.V126.23.1979.1979

Published: 2015

Journal Articles

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies

Yi-Bin Chen, MD, Jennifer Le-Rademacher, PhD, Deidre Marie Kiefer, MPH, Mehdi Hamadani, MD, John F. DiPersio, MD PhD, Mark R Litzow, MD, Michael Craig, MD, Mitchell E. Horwitz, MD, Andrew Artz, MD MS, Brian McClune, DO, Edmund K Waller, MD PhD, Hugo F. Fernandez, MD, Hien Kim Duong, MD, Hati Kobusingye, Mandi Proue, MPH, Rebecca J. Drexler, MPH, Mary M. Horowitz, MD MS, John P. Miller, MD PhD, Steven M. Devine, MD

Blood (2015) 126 (23): 389.

https://doi.org/10.1182/blood.V126.23.389.389

Published: 2015

Journal Articles

Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

Blood (2015) 126 (23): LBA-8.

https://doi.org/10.1182/blood.V126.23.LBA-8.LBA-8

Published: 2015

Journal Articles

Hematopoietic stem cell transplantation for infantile osteopetrosis

Paul J. Orchard, Anders L. Fasth, Jennifer Le Rademacher, Wensheng He, Jaap Jan Boelens, Edwin M. Horwitz, Amal Al-Seraihy, Mouhab Ayas, Carmem M. Bonfim, Farid Boulad, Troy Lund, David K. Buchbinder, Neena Kapoor, Tracey A. O’Brien, Miguel A. Diaz Perez, Paul A. Veys, Mary Eapen

Blood (2015) 126 (2): 270–276.

https://doi.org/10.1182/blood-2015-01-625541

Published: 2015

Journal Articles

Patient-Reported Quality of Life Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: A Secondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

William A. Wood, MD MPH, Jennifer Le-Rademacher, PhD, Mingwei Fei, MS, Brent R. Logan, PhD, Karen L Syrjala, PhD, Navneet S. Majhail, MD MS, John R. Wingard, MD, Muneer H. Abidi, MD, Nancy L. Geller, PhD, Juan Wu, MS, J. Douglas Rizzo, MD, Edward A Faber, DO, MS, Heather Jim, PhD, Paul Jacobsen, PhD, Mary M. Horowitz, MD MS, Stephanie J. Lee, MD MPH

Blood (2014) 124 (21): 206.

https://doi.org/10.1182/blood.V124.21.206.206

Published: 2014

Journal Articles

Low CD34 Cell Dose Is Associated With Higher Non-Relapse and Overall Mortality After Reduced Intensity Conditioning Hematopoietic Cell Transplantation For Acute Myeloid Leukemia and Myelodysplastic Syndrome

Johan Thörlén, MD, Olle Ringdén, MD, PhD, Jennifer Le Rademacher, PhD, Minoo Battiwalla, MD, MS, Junfang Chen, MS, Vincent T. Ho, MD, Partow Kebriaei, MD, Carolyn A. Keever-Taylor, PhD, Tamila L. Kindwall-Keller, DO, Hillard M. Lazarus, MD, Mary J. Laughlin, MD, Michael Lill, MD, BS, Tracey A. O’Brien, FRACP, MBChB, MHL, BSc, Miguel Angel Perales, MD, Vanderson Rocha, MD, PhD, Bipin N. Savani, MD, David Szwajcer, MD, FRCPC, David Valcarcel, MD, Mary Eapen, MBBS, MS

Blood (2013) 122 (21): 3342.

https://doi.org/10.1182/blood.V122.21.3342.3342

Published: 2013

Journal Articles

Provider and Center Characteristics Of US Transplant Centers and Their Association With Survival After Allogeneic Hematopoietic Cell Transplantation (HCT) In Adults: Results From a National Survey Conducted By The Center For International Blood and Marrow Transplant Research (CIBMTR)

Navneet S. Majhail, MD, MS, Tammy Payton, BS, Lih-Wen Mau, PhD, MPH, Jennifer Le Rademacher, PhD, Pintip Chitphakdithai, PhD, Michael Eckrich, MD, Steven Joffe, MD, MPH, Stephanie J. Lee, MD, MPH, Charles F. LeMaistre, MD, Fausto R. Loberiza, Jr., MD, MS, Brent R. Logan, PhD, Elizabeth A Murphy, RN, ScD, Susan K. Parsons, MD, MRP, Ramona Repaczki-Jones, J. Douglas Rizzo, MD, Pam Robinett, Ellen Denzen, MS

Blood (2013) 122 (21): 1687.

https://doi.org/10.1182/blood.V122.21.1687.1687

Published: 2013

NARROW

Modified Staging System for Waldenström Macroglobulinemia (MSS-WM): A Multi-Institutional Externally Validated Prognostic Model for Active/Symptomatic Waldenström Macroglobulinemia

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Apixaban, Dalteparin, in Active Cancer Associated Venous Thromboembolism, the ADAM VTE Trial

Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study

Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials

Transcriptome Analysis of Lymphoma Edited Monocyte Phenotype

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial

PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485)

Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial

Autologous Hematopoietic Cell Transplantation in Patients with High Risk Multiple Myeloma: Post- Transplant Responses Do Not Translate to Longer Survival

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies

Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

Hematopoietic stem cell transplantation for infantile osteopetrosis

Patient-Reported Quality of Life Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: A Secondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

Low CD34 Cell Dose Is Associated With Higher Non-Relapse and Overall Mortality After Reduced Intensity Conditioning Hematopoietic Cell Transplantation For Acute Myeloid Leukemia and Myelodysplastic Syndrome

Provider and Center Characteristics Of US Transplant Centers and Their Association With Survival After Allogeneic Hematopoietic Cell Transplantation (HCT) In Adults: Results From a National Survey Conducted By The Center For International Blood and Marrow Transplant Research (CIBMTR)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only